Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 751 to 800 of 872

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	TA285	22 May 2013	22 May 2013
Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal)	TA286	22 May 2013	22 May 2013
Omalizumab for treating severe persistent allergic asthma	TA278	24 April 2013	24 April 2013
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures	TA279	24 April 2013	24 April 2013
Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis	TA276	27 March 2013	27 March 2013
Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal)	TA277	27 March 2013	27 March 2013
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract	TA272	23 January 2013	23 January 2013
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)	TA273	23 January 2013	23 January 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma	TA268	12 December 2012	12 December 2012
Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal)	TA270	12 December 2012	12 December 2012
Dronedarone for the treatment of non-permanent atrial fibrillation	TA197	25 August 2010	1 December 2012
Ivabradine for treating chronic heart failure	TA267	28 November 2012	28 November 2012
Mannitol dry powder for inhalation for treating cystic fibrosis	TA266	28 November 2012	28 November 2012
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours	TA265	24 October 2012	24 October 2012
Alteplase for treating acute ischaemic stroke	TA264	26 September 2012	26 September 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer	TA263	22 August 2012	22 August 2012
Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	TA261	25 July 2012	25 July 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2	TA257	27 June 2012	27 June 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer	TA258	27 June 2012	27 June 2012
Botulinum toxin type A for the prevention of headaches in adults with chronic migraine	TA260	27 June 2012	27 June 2012
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis	TA254	25 April 2012	25 April 2012
Tocilizumab for the treatment of rheumatoid arthritis	TA247	22 February 2012	22 February 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy	TA242	25 January 2012	25 January 2012
Rituximab for the first-line treatment of stage III-IV follicular lymphoma	TA243	25 January 2012	25 January 2012
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery	TA245	25 January 2012	25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer	TA118	24 January 2007	1 January 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis	TA238	14 December 2011	14 December 2011
Fulvestrant for the treatment of locally advanced or metastatic breast cancer	TA239	14 December 2011	14 December 2011
Ticagrelor for the treatment of acute coronary syndromes	TA236	26 October 2011	26 October 2011
Mifamurtide for the treatment of osteosarcoma	TA235	26 October 2011	26 October 2011
Bortezomib and thalidomide for the first‑line treatment of multiple myeloma	TA228	27 July 2011	27 July 2011
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion	TA229	27 July 2011	27 July 2011
Agomelatine for the treatment of major depressive episodes (terminated appraisal)	TA231	27 July 2011	27 July 2011
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction	TA73	26 November 2003	1 July 2011
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer	TA227	29 June 2011	29 June 2011
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs	TA225	22 June 2011	22 June 2011
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma	TA226	22 June 2011	22 June 2011
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease	TA223	25 May 2011	25 May 2011
Golimumab for the treatment of psoriatic arthritis	TA220	27 April 2011	27 April 2011
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia	TA218	23 March 2011	23 March 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer	TA214	23 February 2011	23 February 2011
Bendamustine for the first-line treatment of chronic lymphocytic leukaemia	TA216	23 February 2011	23 February 2011
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years	TA213	26 January 2011	26 January 2011
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events	TA210	15 December 2010	15 December 2010
Prucalopride for the treatment of chronic constipation in women	TA211	15 December 2010	15 December 2010
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer	TA212	15 December 2010	15 December 2010
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer	TA208	24 November 2010	24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours	TA209	24 November 2010	24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours	TA86	27 October 2004	1 November 2010
Denosumab for the prevention of osteoporotic fractures in postmenopausal women	TA204	27 October 2010	27 October 2010

Results per page

10
25
50
All